Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$1.71 - $3.61 $58,976 - $124,505
34,489 New
34,489 $64,000
Q1 2022

May 16, 2022

SELL
$6.28 - $15.59 $112,386 - $278,998
-17,896 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$14.7 - $28.67 $23,872 - $46,560
-1,624 Reduced 8.32%
17,896 $273,000
Q3 2021

Nov 15, 2021

SELL
$24.31 - $33.6 $71,641 - $99,019
-2,947 Reduced 13.12%
19,520 $555,000
Q2 2021

Aug 16, 2021

BUY
$26.09 - $40.4 $48,892 - $75,709
1,874 Added 9.1%
22,467 $758,000
Q1 2021

May 17, 2021

SELL
$33.06 - $56.93 $4.41 Million - $7.59 Million
-133,340 Reduced 86.62%
20,593 $786,000
Q4 2020

Feb 16, 2021

BUY
$39.09 - $57.4 $4.27 Million - $6.27 Million
109,270 Added 244.65%
153,933 $6.44 Million
Q3 2020

Nov 16, 2020

SELL
$28.43 - $44.67 $5.09 Million - $8 Million
-179,067 Reduced 80.04%
44,663 $1.94 Million
Q2 2020

Aug 14, 2020

BUY
$11.71 - $30.29 $2.62 Million - $6.78 Million
223,730 New
223,730 $6.78 Million
Q4 2019

Feb 18, 2020

SELL
$15.02 - $20.57 $1.65 Million - $2.26 Million
-109,921 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$18.85 - $27.5 $2.13 Million - $3.11 Million
-112,979 Reduced 50.69%
109,921 $2.12 Million
Q2 2019

Aug 14, 2019

BUY
$17.37 - $26.27 $100,746 - $152,366
5,800 Added 2.67%
222,900 $5.24 Million
Q1 2019

May 15, 2019

SELL
$10.65 - $25.75 $1.62 Million - $3.91 Million
-151,786 Reduced 41.15%
217,100 $5.08 Million
Q4 2018

Feb 14, 2019

BUY
$9.26 - $16.38 $2.8 Million - $4.96 Million
302,686 Added 457.23%
368,886 $4.08 Million
Q3 2018

Nov 14, 2018

SELL
$7.54 - $18.31 $412,438 - $1 Million
-54,700 Reduced 45.24%
66,200 $1.11 Million
Q2 2018

Aug 14, 2018

BUY
$4.87 - $8.42 $588,783 - $1.02 Million
120,900 New
120,900 $889,000

Others Institutions Holding NVTA

About Invitae Corp


  • Ticker NVTA
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 235,266,000
  • Description
  • Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...
More about NVTA
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.